Vident Advisory, LLC Autolus Therapeutics PLC Transaction History
Vident Advisory, LLC
- $10.5 Trillion
- Q3 2025
Shares
1 transactions
Others Institutions Holding AUTL
# of Institutions
103Shares Held
150MCall Options Held
24.6KPut Options Held
41.9K-
Mak Capital One LLC New York, NY26MShares$36.2 Million6.54% of portfolio
-
Blackstone Inc New York, NY20.5MShares$28.5 Million0.15% of portfolio
-
Syncona Portfolio LTD Guernsey, Channel Islands, X016.6MShares$23.1 Million97.83% of portfolio
-
Armistice Capital, LLC New York, NY15.6MShares$21.7 Million0.39% of portfolio
-
Tfg Asset Management Gp LTD Grand Cayman, E99.5MShares$13.2 Million3.44% of portfolio
About Autolus Therapeutics plc
- Ticker AUTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 90,909,800
- Market Cap $126M
- Description
- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...